It hasn’t been a great year for Alzheimer’s drugs—or really a great decade, even. The most recent Phase 3 trial cancellation was a study…
After an Alzheimer’s diagnosis, many caregivers and patients feel as if they are sent away with a pamphlet, pills and little concrete advice on…
On Thursday, Biogen, along with its Japanese partner Eisai, announced it would be canceling two late-stage trials testing their drug aducanumab. The drug was…
Jeff Borghoff and his wife Kimberly speak about participating in the Biogen drug trial testing aducanumab, a drug that targets beta-amyloid. The late-stage trial…
Dementia is steadily rising in the ranks of causes of death in America, according to a new report released by the National Center for…
We know that Alzheimer’s is caused by a combination of genetics and environmental factors. But for some people, the chances of getting Alzheimer’s are…
It sounds like something out of a science fiction movie with a Goop-esque twist: a company called Ambrosia offers plasma transfusions of “young” blood into…
First it was a diabetes drug, now researchers have turned their attention to an HIV drug. Could a drug that would slow down Alzheimer’s…
A number of biotechs have aimed to resolve Alzheimer’s via a vaccine over recent years, only to call it off due to nasty side…
Like literally millions who have lost a loved one to Alzheimer’s disease, my family was devastated when my grandfather, Stanley Friedman, was taken from…
Does a drug that could treat Alzheimer’s already exist? A new study suggests that people with Alzheimer’s given a diabetes drug had fewer signs…
The long search for a drug to slow the decline of Alzheimer’s may have reached a turning point. Pharmaceutical companies Biogen and Eisai have…
After years of failure, including some pharmaceutical companies calling off Alzheimer’s research altogether, Biogen offers a glimmer of hope: New data from a Phase…
Any Alzheimer’s drug under development has a complicated journey from formulation to clinical trials to potentially getting in the hands of patients. We spoke…
Another Alzheimer’s drug has failed in a phase 3 trial, the stage right before drugs go to the Food and Drug Administration for approval….